MindMed
MMED
$17.49
-2.83%
MiniMed Group, Inc. is a medical device company focused on diabetes management, commercializing insulin pump therapy, continuous glucose monitors (CGMs), smart insulin pens, and related consumables — a portfolio it pioneered in the 1980s before being acquired by Medtronic in 2001 and spun back out as an independent public company in March 2026. MiniMed is the market leader in traditional tubed insulin pumps, a legacy franchise that gives it an installed base and consumable-driven revenue stream, but it competes in an increasingly crowded diabetes technology arena against patch-pump and next-generation CGM rivals. The investor narrative centers on the spin-off mechanics — Medtronic still owns roughly 90% of shares pending a tax-free distribution to its shareholders — creating a technical overhang and index-inclusion dynamics, while the fundamental debate hinges on whether MiniMed can defend its pump leadership and accelerate CGM adoption against faster-growing competitors. Recent headlines flagging strong earnings from both MDT and MMED have reinforced the turnaround/standalone-execution story, with the market focused on margin recovery, revenue reacceleration, and the timing of the distribution that will float the full share count.…
MMED
MindMed
$17.49
Related headlines
Investment Opinion: Should I buy MMED Today?
Rating: Hold with a constructive bias. The thesis is that MiniMed is a genuine turnaround trading at a deep discount to medtech peers on sales (1.09x PS) with unanimous analyst support (16 analysts, mean rating 1.625, average target $25.19 implying +44.0% upside), but the negative free cash flow and unproven margin recovery argue for patience rather than aggressive accumulation at $17.49. The consensus buy rating and $25.19 target anchor the view that the recent 21.9% one-month drawdown is an overreaction, yet the $15.00 low target and 6.07 short ratio warn that conviction is not uniform.
Supporting evidence: revenue grew 16.44% YoY to $843 million in Q1 2026, the fifth consecutive sequential increase; net income swung from -$183 million in Q4 2025 to roughly breakeven, with operating income of $38 million (4.51% margin); the balance sheet is lightly levered at 0.040 debt-to-equity with a 1.92 current ratio and $207 million cash; and the stock trades at 1.09x PS and 0.94x PB versus 3–6x sales for large-cap medtech peers. The implied +44.0% upside to the $25.19 average target, against only -14% to the $15.00 low target, gives a favorable risk/reward skew on the sell-side view, though the -$316 million TTM free cash flow and 25.19x forward PE on $3.20 consensus EPS mean the income statement must deliver.
Risks and conditions: the biggest threats are continued cash burn (-$316 million TTM FCF), margin compression (gross margin down to 55.16% from 57.35%), and the ~90% Medtronic ownership overhang ahead of the tax-free distribution. This Hold would upgrade to Buy if free cash flow turns positive or gross margin stabilizes above 57% while revenue growth holds above 15%, or if the stock pulls back toward the $15.00 analyst low target; it would downgrade to Sell if revenue growth decelerates below 10%, gross margin falls below 54%, or the distribution is delayed in a way that prolongs the overhang. Valuation verdict: the stock is cheap on sales and book relative to peers but expensive on forward earnings — fairly valued to slightly undervalued for a turnaround with this much execution risk, not a clear bargain.
Sign up to view all
MMED 12-Month Price Forecast
MiniMed offers a favorable risk/reward skew on paper — 44% upside to the average target versus only 14% downside to the low target — but the valuation is split between a deep discount on sales and a premium on forward earnings that requires a dramatic EPS swing from roughly breakeven to $3.20. The turnaround is real (net income improved from -$183 million in Q4 2025 to breakeven in Q1 2026), yet -$316 million TTM free cash flow and 55.16% gross margin show the company is not yet self-funding. The ~90% Medtronic ownership overhang is both the key technical risk and the key catalyst: a clean tax-free distribution could unlock index inclusion and close the peer discount, while a delay or disorderly execution could pressure the stock. I would upgrade to bullish if free cash flow turns positive or gross margin recovers above 57% with revenue growth holding above 15%, and downgrade to bearish if revenue growth falls below 10% or another capital raise is announced.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on MindMed's 12-month outlook, with a consensus price target around $25.19 and implied upside of +44.0% versus the current price.
Average Target
$25.19
0 analysts
Implied Upside
+44.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$15 - $30
Analyst target range
Coverage is robust with 16 analysts, and sentiment is decisively bullish: the consensus recommendation is "buy" with a recommendation mean of 1.625 (where 1.0 is a strong buy), and the average target price of $25.19 implies +44.0% upside from the current $17.49 — a wide gap that suggests the sell-side views the recent 21.9% one-month drawdown as an overreaction rather than a fundamental break. The institutional ratings list shows a wall of Buy/Overweight/Outperform ratings from Morgan Stanley, Evercore ISI, Mizuho, BofA, Wells Fargo, Citigroup, UBS, and BTIG, all reaffirmed in early September 2026 with no downgrades, indicating strong conviction among covering firms.
The target range spans $15.00 to $30.00 — a $15 spread, or roughly 86% of the current price — signaling meaningful disagreement about the standalone story. The $30 high target likely assumes successful margin expansion toward peer medtech levels, accelerating CGM adoption, and a clean tax-free distribution that unlocks index inclusion and broader ownership; the $15 low target, only 14% below the current price, prices in continued margin compression, competitive share loss in pumps, and cash burn requiring further capital raises. The tight clustering of ratings around Buy with a $25.19 average versus a $17.49 price implies the market is discounting execution risk more heavily than analysts are, and the absence of any recent downgrades despite the sharp pullback is a modest positive signal — though the wide target dispersion and 6.07 short ratio warn that conviction is not uniform.
Bulls vs Bears: MMED Investment Factors
The bull case rests on a genuine turnaround — revenue up 16.44% YoY, a swing from -$183M net loss in Q4 2025 to breakeven in Q1 2026, a 1.09x PS ratio at a deep discount to medtech peers, and a unanimous buy consensus with a $25.19 average target implying 44% upside. The bear case counters with -$316M TTM free cash flow, a forward PE of 25.19x that prices a dramatic swing to $3.20 EPS, margin compression to 55.16% gross and 4.51% operating, and a -21.9% one-month momentum breakdown with a 6.07 short ratio. On balance, the bull evidence is currently stronger on valuation and analyst conviction, but the bear evidence is stronger on cash generation and near-term price action. The single most important tension is whether the breakeven quarter marks the start of durable margin expansion toward peer levels or a temporary reprieve before further cash burn — resolution of that question, alongside the timing of the Medtronic tax-free distribution, will determine whether the 44% analyst upside is realized or the stock retests its $10.65 low.
Bullish
- Analyst consensus implies 44% upside: All 16 covering analysts rate MMED a buy (mean 1.625), with an average target of $25.19 versus the $17.49 current price — +44.0% upside. The $15.00 low target sits only 14% below the current price, meaning even the most bearish analyst sees limited downside from here.
- Revenue growth accelerating sequentially: Q1 2026 revenue of $843 million grew 16.44% YoY and marked the fifth consecutive sequential increase from $752M (Q2 2025) to $790M, $837M, and $843M. Consensus FY revenue of ~$5.05 billion implies continued growth, and the recurring consumables base ($261M in Q1) provides a durable revenue floor.
- Swing to breakeven from deep losses: Net income improved from -$183M in Q4 2025 and -$119M in Q3 2025 to roughly $0 in Q1 2026, with operating income turning positive at $38M (4.51% margin). This is genuine turnaround progress that, if sustained, would justify the forward PE of 25.19x on consensus EPS of $3.20.
- Deep discount on sales versus peers: PS of 1.09x and EV/Sales of 1.53x are far below the 3–6x typical of large-cap medtech peers, and PB of 0.94x is below book value. The discount is partly explained by the ~90% Medtronic ownership overhang, which should narrow as the tax-free distribution floats the full share count and unlocks index inclusion.
Bearish
- Negative free cash flow of -$316M TTM: FCF TTM is -$316 million, Q1 2026 operating cash flow was -$49 million with $41 million capex, and working capital consumed $110 million in the quarter. The company is not self-funding and depends on capital markets and the Medtronic relationship — a material risk if the distribution is delayed or sentiment sours.
- Forward PE of 25.19x prices a dramatic swing: Trailing EPS is -$0.098 (PE of -10.23x) while the forward PE of 25.19x embeds consensus EPS of $3.20 — an enormous jump from roughly breakeven. The market is paying a premium on forward earnings for a company that has not yet demonstrated sustained profitability, leaving little room for execution error.
- Margin compression and thin operating profitability: Gross margin fell to 55.16% in Q1 2026 from 57.35% in Q4 2025 and 56.91% in Q2 2025, while operating margin is only 4.51% — far below the high-teens-to-20%+ typical of scaled medtech peers. ROE of -9.17% and a net margin of -10.67% confirm the profitability gap.
- Momentum breakdown with -21.9% one-month drop: The stock fell 21.92% over the past month versus a +1.22% gain for the S&P 500, a relative strength of -23.14 percentage points, and dropped from $19.71 on October 9 to $16.81 on October 14 on elevated volume of 21.45 million shares. The 6.07 short ratio means bears have built a meaningful position that could amplify further downside.
MMED Technical Analysis
MiniMed is in a recovery uptrend that has stalled into a corrective phase: the stock is up 21.12% over six months and 3.31% over three months, but sits 28.4% below its 52-week high of $24.43 and 64.2% above its 52-week low of $10.65, placing the current $17.49 price at roughly 71.6% of its 52-week range. That positioning is neither a breakout nor a falling knife — it reflects a stock that rallied hard off its April lows near $10.65 but has surrendered a meaningful chunk of its summer gains, leaving it in the upper-middle of its range with momentum deteriorating.
Short-term momentum has clearly decelerated and now diverges sharply from the medium-term trend: the stock is down 21.92% over the past month versus a +1.22% gain for the S&P 500, a relative strength reading of -23.14 percentage points, while the three-month change remains positive at +3.31% and six-month at +21.12%. This divergence — a strong six-month base with a violent one-month drawdown — signals a momentum reversal or mean-reversion event rather than a simple pullback, and the most recent sessions confirm the weakness: the stock fell from $19.71 on October 9 to $16.81 on October 14 before a modest bounce to $17.49, with the -2.83% single-day decline on the latest print accompanied by elevated volume of 21.45 million shares. The 6.07 short ratio suggests bears have built a meaningful position, which could amplify either a squeeze or further downside.
Key technical levels are well defined: support sits at the $16.81 recent low and, more importantly, the $10.65 52-week low, while resistance is anchored at the $24.43 52-week high with intermediate supply around $22–$23 where the September rally stalled. A breakout above $24.43 would signal a full trend resumption and likely force short covering, whereas a breakdown below $16.81 would open the door to a retest of the low-$teens and potentially the April lows. The stock's max drawdown of -41.59% over the period underscores elevated volatility, and while beta is not provided, the 21.45 million share volume and 6.07 short ratio imply a high-beta, event-driven trading profile that warrants smaller position sizing and wider stops.
Beta
—
—
Max Drawdown
-41.6%
Largest decline past year
52-Week Range
$11-$24
Price range past year
Annual Return
—
Cumulative gain past year
| Period | MMED Return | S&P 500 |
|---|---|---|
| 1m | -21.9% | +0.2% |
| 3m | +3.3% | +2.9% |
| 6m | +21.1% | +8.4% |
| 1y | — | +14.9% |
| ytd | — | +11.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MMED Fundamental Analysis
Revenue is growing at a solid but moderating pace: the most recent quarter (Q1 2026, ended July 31, 2026) delivered $843 million in revenue, up 16.44% year-over-year, building on a sequential trajectory of $752 million (Q2 2025), $790 million (Q3 2025), $837 million (Q4 2025), and now $843 million — a consistent upward march that implies roughly $3.2–3.4 billion in annualized revenue. Segment data shows Consumables at $261 million, Pumps at $144 million, and Other product/service at $7 million, confirming that the recurring consumables base is the largest single revenue driver and the pump franchise the second — a mix that supports recurring revenue but exposes the company to competitive pressure in the pump hardware cycle. The 16.44% growth rate is respectable for a mature medtech franchise but well below the growth rates of CGM pure-plays, which is the core of the bear case.
Profitability is thin but improving: Q1 2026 gross margin was 55.16% ($465 million gross profit on $843 million revenue), down from 57.35% in Q4 2025 and 56.91% in Q2 2025, indicating modest margin compression, while operating income of $38 million (4.51% operating margin) and net income of roughly zero (EPS of $0.00, net margin 0.00%) show the company is only just at breakeven. The prior quarters were materially worse — Q4 2025 posted a net loss of $183 million (-21.86% net margin) and Q3 2025 a loss of $119 million (-15.06%) — so the swing to breakeven represents genuine progress, but the 4.51% operating margin is far below the high-teens-to-20%+ margins typical of scaled medical device peers, leaving substantial room for either expansion or disappointment.
Balance sheet and cash flow are the weak spot: free cash flow TTM is -$316 million, Q1 2026 operating cash flow was -$49 million with capex of -$41 million (FCF of -$90 million), and the company burned $110 million of working capital in the quarter, though it holds $207 million in cash against a debt-to-equity ratio of just 0.040 and a current ratio of 1.92 — a low-leverage but cash-hungry profile. ROE is -9.17% and the PCF ratio of -17.19 reflects negative cash generation, meaning the company is not yet self-funding and depends on the Medtronic relationship and capital markets; the Q4 2025 $538 million common stock issuance and $512 million net financing inflow confirm external funding reliance. The 54.16% gross margin and 1.58% operating margin (per valuation data) versus the 4.51% quarterly operating margin highlight volatility in reported profitability, and the negative FCF yield is the key risk to monitor.
Quarterly Revenue
$843000000.0B
2026-07
Revenue YoY Growth
+16.4%
YoY Comparison
Gross Margin
55.2%
Latest Quarter
Free Cash Flow
$-316000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MMED Overvalued?
Because trailing net income is negative (EPS of -$0.098, trailing PE of -10.23), the PE ratio is not meaningful and I am leading with the PS ratio of 1.09x and EV/Sales of 1.53x as the primary metrics, supplemented by the forward PE of 25.19x. The gap between the negative trailing PE and the positive forward PE of 25.19x implies the market expects a dramatic swing to profitability — consistent with consensus estimated EPS of $3.20 — which is an aggressive assumption for a company currently earning roughly zero; the forward multiple therefore embeds significant execution risk.
Against the medical equipment sector, a PS of 1.09x and EV/Sales of 1.53x are notably cheap — large-cap medtech peers typically trade at 3–6x sales — but that discount is explained by the negative net margin (-10.67%), negative FCF, and the ~90% Medtronic ownership overhang rather than by superior fundamentals. The EV/EBITDA of 15.78x is closer to sector norms and suggests the enterprise value is not distressed, while the PB ratio of 0.94x (below book) signals the market is skeptical of the asset base's earning power; the PEG ratio of -0.23 is meaningless given negative earnings. On balance, the stock trades at a deep discount to peers on sales but a premium on forward earnings, a split valuation that reflects a turnaround priced for success on the income statement but not yet on the top line.
Historically, the stock's own PS ratio has ranged from 4.23x (Q4 2025) to 6.57x (Q3 2025) to 6.02x (Q1 2026) on the historical ratios data, versus the current 1.09x — a dramatic compression that partly reflects the post-spin share-count and market-cap recalibration but also signals the market has de-rated the equity. The PB ratio has fallen from 1.50x (Q3 2025) to 0.94x now, near the bottom of its short public history, which suggests either a value opportunity if margins inflect or fundamental deterioration if the pump franchise erodes; given the negative FCF and breakeven earnings, the burden of proof remains on execution.
PE
-10.2x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are dominated by cash burn: free cash flow TTM is -$316 million, Q1 2026 operating cash flow was -$49 million against $41 million of capex, and working capital consumed $110 million in the quarter, leaving the company dependent on external funding — evidenced by the $538 million equity issuance in Q4 2025 and $512 million net financing inflow. Profitability is thin and volatile, with Q1 2026 operating margin of 4.51% and net income of roughly zero following net losses of $183 million in Q4 2025 and $119 million in Q3 2025, while gross margin compressed to 55.16% from 57.35% sequentially. Revenue concentration adds risk: consumables ($261 million) and pumps ($144 million) dominate the $843 million quarterly top line, so any share loss in the legacy tubed-pump franchise would hit both hardware and the recurring consumable stream that depends on it. The forward PE of 25.19x on consensus EPS of $3.20 means the valuation requires continued growth and margin recovery to be justified, leaving little cushion for operational disappointment.
Market and competitive risks center on valuation compression and competitive disruption. The stock trades at a split valuation — 1.09x PS and 1.53x EV/Sales at a deep discount to the 3–6x typical of medtech peers, but 25.19x forward earnings at a premium — so any failure to deliver the expected earnings swing would compress the forward multiple sharply. Competition from patch-pump and next-generation CGM rivals threatens the traditional tubed-pump leadership that underpins the franchise, and the 16.44% growth rate trails CGM pure-plays. The ~90% Medtronic ownership overhang creates a technical supply risk: the pending tax-free distribution will float a much larger share count, and its timing and mechanics could pressure the stock regardless of fundamentals. Momentum risk is acute — the stock fell 21.92% in the past month versus a +1.22% S&P 500 gain (relative strength -23.14 points) — and the 6.07 short ratio means bearish positioning could amplify volatility in either direction; with a max drawdown of -41.59% over the period, position sizing should be conservative.
Worst-case scenario: the breakeven quarter proves temporary, gross margin continues eroding below 55%, and free cash flow remains deeply negative, forcing another equity raise that dilutes holders just as the Medtronic distribution floods the market with shares. In that chain, the forward EPS of $3.20 is missed, the 25.19x forward multiple compresses toward the sector's low end, and the stock retests its 52-week low of $10.65 — a decline of roughly -39% from the current $17.49. The analyst low target of $15.00 implies a milder -14% downside, but the April 2026 trading range near $10.65–$11.00 shows the stock can trade there; a full retest of the low would erase about 39% of capital, and a break below it would open further downside toward the low-$10s.
FAQ
Ranked by severity: first, financial risk — free cash flow TTM of -$316 million and Q1 2026 operating cash flow of -$49 million mean the company depends on external funding, with a dilutive equity raise a real possibility. Second, company-specific execution risk — the 25.19x forward PE on $3.20 consensus EPS requires a dramatic swing from breakeven, and gross margin compression to 55.16% from 57.35% shows the trend is not yet favorable. Third, competitive risk — MiniMed's leadership is in traditional tubed pumps, a franchise facing patch-pump and next-generation CGM rivals, and its 16.44% growth trails CGM pure-plays. Fourth, macro/technical risk — the ~90% Medtronic ownership overhang ahead of the tax-free distribution, a 6.07 short ratio, and a -41.59% max drawdown make the stock event-driven and volatile, with a -21.9% one-month decline versus a +1.22% S&P 500 gain underscoring the momentum breakdown.
The 12-month forecast has three scenarios: a 30% probability bull case targeting $25.19–$30.00 (durable margin recovery, positive free cash flow, clean distribution and index inclusion), a 50% probability base case targeting $17.49–$25.19 (mid-teens revenue growth, modest margin improvement, distribution on schedule, stock grinding toward the average target), and a 20% probability bear case targeting $10.65–$15.00 (margin erosion, continued cash burn, dilutive raise, retest of the 52-week low). The base case is most likely, with the key assumption being that revenue growth holds in the 14–17% range and gross margin stabilizes near 55–57%. The wide $15–$30 analyst target range reflects genuine disagreement, and the 6.07 short ratio means the path will likely be volatile regardless of direction.
The valuation is split. On sales, MMED is cheap: PS of 1.09x and EV/Sales of 1.53x versus the 3–6x typical of large-cap medtech peers, and PB of 0.94x is below book value. On forward earnings, it is expensive: the 25.19x forward PE embeds consensus EPS of $3.20 against trailing EPS of -$0.098, requiring a dramatic swing to profitability. The stock's own PS history has compressed from 6.57x in Q3 2025 to 1.09x now, partly a post-spin recalibration but also a de-rating. The market is paying a discount on the top line and a premium on the income statement, implying it expects the turnaround to succeed on earnings but is not yet convinced on revenue durability. Net: fairly valued to slightly undervalued for a turnaround with this execution risk, not a clear bargain.
From a risk/reward perspective, MMED offers +44.0% upside to the $25.19 average analyst target against only -14% to the $15.00 low target, a favorable skew supported by 16 buy-rated analysts and a 1.09x PS ratio at a deep discount to medtech peers. However, the biggest downside risk is real: -$316 million TTM free cash flow and a 25.19x forward PE on $3.20 consensus EPS mean the company must deliver a dramatic earnings swing, and a miss could send the stock toward its $10.65 low, roughly -39% from $17.49. The recent 21.9% one-month drawdown and 6.07 short ratio add near-term volatility. It is a good buy for risk-tolerant investors with a 12–24 month horizon who believe in the margin recovery story and can stomach a potential retest of the low; more conservative investors should wait for positive free cash flow or a pullback toward $15 before accumulating.
MMED is better suited to a medium-to-long-term holding period of at least 12–24 months rather than short-term trading. The turnaround thesis — margin recovery from 4.51% operating margin toward peer levels, free cash flow inflecting from -$316 million TTM, and the Medtronic distribution unlocking index inclusion — requires multiple quarters to play out, and the stock's -41.59% max drawdown and 6.07 short ratio make short-term price action highly unpredictable. There is no dividend (payout ratio 0, yield 0), so returns depend entirely on capital appreciation, and the 25.19x forward PE means earnings visibility is still limited. Short-term traders could trade the well-defined $16.81 support and $22–$23 resistance levels, but the event-driven nature of the distribution and quarterly earnings makes a buy-and-hold approach with a 12–24 month minimum more appropriate for the core thesis.